Variantyx develops proprietary, clinically-accredited whole genome analysis platforms for genetic disorders, reproductive health, and precision oncology. The company reports sequencing tens of thousands of genomes to date. It has seen a rapid increase in test volumes in Q1 2024 and is expanding its market share as demand shifts from panel and exome testing to whole genome testing. Variantyx says it maintains strong unit economics while aiming to provide genome-based care to a larger number of patients. The company plans ongoing innovation of new genome analysis technologies and will use new capital for technological and commercial expansion. Variantyx is based in Framingham, Mass., and has attracted more than $125 million in total investment to date. Variantyx develops a proprietary whole-genome analysis platform that provides advanced genomic testing for rare genetic disorders, reproductive health, and precision oncology. Its precision oncology solution combines multiple genomic technologies to identify tumor-specific genetic alterations to help predict therapy response, optimize management, and provide prognostic and clinical-trial information. The company says its platform offers unmatched diagnostic capabilities and improved personalized treatment recommendations. Variantyx is targeting growth in North America and Europe, which it cites as key regions for precision medicine spending. Management intends to scale commercial efforts to take advantage of the growing global precision medicine market. The company recently strengthened its capital position through a debt financing to support that growth. Variantyx is a technology-driven precision medicine company based in Framingham, Mass., providing advanced genomic testing for rare genetic disorders, reproductive health, and precision oncology. The company has developed proprietary whole genome analysis platforms that enable clinicians and patients to understand a person’s genetic makeup. These platforms aim to improve diagnostic capabilities and support personalized treatment recommendations. Led by CEO Haim Neerman, Variantyx provides solutions across diagnostics and oncology markets. The company raised $41.5M in a Series C-2 to accelerate growth and bring newly developed solutions to market. Variantyx plans to focus the investment on expanding its precision oncology offerings while scaling across its other target markets. Variantyx provides Genomic Unity, a WGS-based single-method testing program that identifies multiple variant types from a single patient sample and issues a unified clinical report. The company’s WGS methodology is used to diagnose rare inherited and neurological disorders and is being positioned as a first-line test to reduce the diagnostic odyssey. Variantyx has also announced a WGS-based prenatal test for high-risk pregnancies with ultrasound anomalies. The company recently secured $20M in Series C funding to extend its technology into comprehensive tumor diagnostic solutions and to expand sales. Management says the funding will enable faster diagnosis and implementation of personalized treatment plans for cancer patients. Variantyx operates as a high-complexity hereditary disease testing laboratory under CLIA/CAP.

Total raised

$118M

Funding rounds

4

Latest round

Equity

Latest activity

Apr 2024